^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

ALK positive

i
Other names: NBLST3, CD246, Anaplastic Lymphoma Kinase, Anaplastic Lymphoma Kinase (Ki-1), CD246 Antigen, Mutant Anaplastic Lymphoma Kinase, ALK, ALK Receptor Tyrosine Kinase, Anaplastic Lymphoma Receptor Tyrosine Kinase, ALK Tyrosine Kinase Receptor
Entrez ID:
Related tests:
1d
Epidemiology, clinical features, and outcomes of peripheral T-cell lymphoma in Latin America: an international, retrospective, cohort study. (PubMed, Lancet Haematol)
Our study underscores the unique epidemiological profile of peripheral T-cell lymphoma in Latin America, with a high prevalence of adult T-cell leukaemia or lymphoma and extranodal natural killer T-cell lymphoma. These findings present a crucial opportunity to prioritise clinical trials on these rare subtypes of peripheral T-cell lymphoma by integrating Latin American countries into global research. However, our findings require further validation in robust epidemiological studies.
Retrospective data • Journal
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive • ALK negative
|
doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone
4d
Ensartinib for EML4-ALK-positive lung adenocarcinoma with comorbid mutations in TP53, EGFR, and ERBB2: a case report. (PubMed, Front Oncol)
This case demonstrates the potential for ensartinib in the treatment of EML4-ALK+ lung adenocarcinoma with multiple gene mutations. Further investigation through clinical trials is needed to evaluate the safety and efficacy of this targeted therapy.
Journal
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • EML4 (EMAP Like 4)
|
TP53 mutation • EGFR mutation • HER-2 mutation • ALK positive • ALK rearrangement
|
Ensacove (ensartinib)
4d
ALK-positive anaplastic large cell lymphoma initially diagnosed as neurosarcoidosis in a 12-year-old girl. (PubMed, J AAPOS)
The patient's vision returned after initiation of chemotherapy. This case highlights the importance of considering malignancy in the differential for optic neuritis.
Journal
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive
6d
Brigatinib can inhibit proliferation and induce apoptosis of human immortalized keratinocyte cells. (PubMed, Front Pharmacol)
In addition, we demonstrated that brigatinib reduced the protein expression of amphiregulin, epiregulin, TGFA, PI3K, AKT and phosphorylated AKT (p-AKT). This study confirms the inhibition of HaCaT cells growth and progression by brigatinib and highlights the potential value of the PI3K/AKT pathway as a therapeutic target for brigatinib-induced dermal toxicities.
Journal
|
ALK (Anaplastic lymphoma kinase) • AREG (Amphiregulin) • EREG (Epiregulin) • TGFA (Transforming Growth Factor Alpha)
|
ALK positive
|
Alunbrig (brigatinib)
7d
Anti-ALK autoantibodies in patients with ALK-positive Non-Small Cell Lung Cancer (NSCLC): A monocentric experience. (PubMed, J Liq Biopsy)
This is the first investigation to explore the impact of circulating anti-ALK a-abs on BM. Prospective studies with longer follow-up are warranted to further explore the impact of anti-ALK a-abs on BM.
Journal
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive • ALK rearrangement • ALK fusion
7d
NGS detection of gene rearrangements and METexon14 mutations in liquid biopsy of advanced NSCLC patients: A study of two Italian centers. (PubMed, J Liq Biopsy)
ctDNA testing to detect oncogenic fusions or METexon14 mutations in advanced NSCLC patients is useful, even if type of gene alterations and clinical characteristics could influence the driver detection rate. Liquid biopsy represents a complementary tool to tissue genotyping, however more sensitive approaches for gene fusions and METexon14 detection are needed to implement its strength and reliability.
Journal • Liquid biopsy • Next-generation sequencing
|
KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • MET (MET proto-oncogene, receptor tyrosine kinase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • SMAD4 (SMAD family member 4)
|
TP53 mutation • KRAS mutation • NRAS mutation • ALK positive • RET fusion • ALK rearrangement • ALK fusion • ALK mutation • ROS1 fusion • ROS1 positive • ROS1 rearrangement • RET positive
|
AVENIO ctDNA Expanded Kit
8d
First-line lorlatinib versus crizotinib in Asian patients with advanced ALK-positive NSCLC: 5-year outcomes from the CROWN study. (PubMed, J Thorac Oncol)
After 5 years of follow-up, lorlatinib efficacy and safety in the Asian subgroup of CROWN continue to be consistent with those in the overall population, with PFS remaining unreached with lorlatinib.
Journal
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive
|
Xalkori (crizotinib) • Lorbrena (lorlatinib)
12d
Laparoscopic partial cystectomy using stapling system for inflammatory myofibroblastic tumor of urinary bladder: A case report. (PubMed, SAGE Open Med Case Rep)
Subsequently, she underwent laparoscopic partial cystectomy using the Signia Stapling System due to the low-grade malignancy of the tumor. The patient has been under outpatient observation with no recurrence for 12 months post-surgery.
Journal
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive
12d
Safety and Effectiveness of Brigatinib in Anaplastic Lymphoma Kinase (ALK) Positive Metastatic Non-Small Cell Lung Cancer (NSCLC) in Argentina: A Post-Marketing Surveillance Study. (PubMed, Drugs Real World Outcomes)
Brigatinib was demonstrated to be a safe and effective treatment option for ALK-positive metastatic non-small cell lung cancer in routine clinical practice in Argentina.
P4 data • Journal
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive
|
Alunbrig (brigatinib)
12d
APG-2449 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=150, Recruiting, Ascentage Pharma Group Inc. | Trial completion date: Feb 2025 --> Jan 2028 | Trial primary completion date: Jan 2025 --> Dec 2027
Trial completion date • Trial primary completion date
|
ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
ALK positive • ROS1 fusion • ROS1 positive
|
APG-2449
12d
Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer (clinicaltrials.gov)
P2, N=26, Recruiting, Pingping Song | Not yet recruiting --> Recruiting | Trial completion date: Jul 2025 --> Apr 2028 | Trial primary completion date: Mar 2025 --> Jan 2026
Enrollment open • Trial completion date • Trial primary completion date
|
ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
ALK positive • ROS1 positive
|
Qi Xinke (iruplinalkib)
14d
FDG PET/CT in ALK-positive Histiocytosis of the Nasal Cavity in a Pediatric Patient. (PubMed, Clin Nucl Med)
We present FDG PET/CT findings in a pediatric patient with ALK-positive histiocytosis isolated to the left nasal cavity. The nasal cavity tumor invaded the nasal septum, left nasal bone, and left ethmoid sinus and showed intense FDG activity with an SUVmax of 9.9.
Journal
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive
14d
Development of an ALK-positive Non-Small-Cell Lung Cancer in Vitro Tumor 3D Culture Model for Therapeutic Screening. (PubMed, J Histochem Cytochem)
When we investigated the effect of the combination of alectinib and SHP099 in these novel 3D cultures, we found a comparable cellular response compared with our two-dimensional experiments especially with the drugs in combination. We suggest that 3D cultures be used as preclinical screening platforms to ensure that only the most efficacious drug candidates move on to in vivo testing.
Preclinical • Journal
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive
|
Alecensa (alectinib) • SHP099
17d
Expanding the spectrum of FUS::CREM-rearranged neoplasms: a case of mesenchymal malignant tumor with neuroendocrine differentiation. (PubMed, Virchows Arch)
A FUS (exon 7)::CREM (exon 6) fusion was detected in two tumors and confirmed by FISH. This paraganglioma-like malignant neoplasm may belong to the group of FET::CREB-rearranged mesenchymal neoplasms, currently in the course of delineation, and points to its phenotypic diversity.
Journal
|
ALK (Anaplastic lymphoma kinase) • FUS (FUS RNA Binding Protein) • CD99 (CD99 Molecule) • CREM (CAMP Responsive Element Modulator) • GATA3 (GATA binding protein 3) • PHOX2B (Paired Like Homeobox 2B)
|
ALK positive
18d
SMARCB1-deficient Medullary-Like Renal Cell Carcinoma Without SMARCB1/INI1 Gene Deletion. (PubMed, Int J Surg Pathol)
The presence of perirenal lymph node metastases and recurrence despite nephrectomy is indicative of the poor prognosis of this tumor. Further investigation of the relationship between the loss of SMARCB1 protein and the development of RCCU-MP might improve our understanding of the pathogenesis of this malignant tumor.
Journal
|
ALK (Anaplastic lymphoma kinase) • SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1) • KRT19 (Keratin 19) • GATA3 (GATA binding protein 3) • PAX2 (Paired Box 2) • PAX8 (Paired box 8)
|
ALK positive
18d
Neurological symptom management in breast cancer meningeal carcinomatosis. (PubMed, Transl Breast Cancer Res)
In recent years, systemic therapies such as trastuzumab deruxtecan and tucatinib have been reported effective for human epidermal growth factor receptor 2 (HER2)-positive breast cancer, however, these cannot be used for all MC. In the future, if a lineup of highly effective systemic therapies such as tyrosine kinase inhibitors for ALK gene-positive lung cancer is established, treatment strategies for MC may change. However at present, rapid diagnosis and prompt neurological palliative treatment play an important role in the neurological symptoms management of MC.
Review • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ALK (Anaplastic lymphoma kinase)
|
ALK positive • EGFR positive
|
Enhertu (fam-trastuzumab deruxtecan-nxki) • Tukysa (tucatinib)
18d
Unraveling the unforeseen: anuric acute kidney injury induced by alectinib. (PubMed, Hosp Pract (1995))
Early recognition and prompt intervention are crucial to mitigate renal complications and optimize patient outcomes. Brigatinib may serve as a suitable alternative for patients intolerant to alectinib.
Journal
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive
|
Alecensa (alectinib) • Alunbrig (brigatinib)
19d
PLCXD3-ALK, a novel ALK rearrangement in lung squamous cell carcinoma and its clinical responses to ALK inhibitors. (PubMed, J Thorac Dis)
The activation of downstream pathways and the response to ALK inhibitors crizotinib and alectinib were demonstrated by western blotting (WB). We identified and functionally validated PLCXD3-ALK as a novel rare fusion in NSCLC that has not been previously reported. It can serve as a meaningful therapeutic target for ALK inhibitors of ALK + NSCLC.
Journal
|
ALK (Anaplastic lymphoma kinase) • EML4 (EMAP Like 4)
|
ALK positive • ALK rearrangement • ALK fusion • ALK mutation
|
Xalkori (crizotinib) • Alecensa (alectinib)
20d
A Case of Relapsed and Refractory Pediatric Anaplastic Large Cell Lymphoma with Complex Karyotype. (PubMed, Clin Lab)
This case underscores the aggressive nature of pediatric ALCL with complex karyotypes and highlights the challenges associated with its treatment. Despite intensive chemotherapy, the disease exhibited rapid relapse and resistance, ultimately leading to a fatal outcome. This report contributes to the limited literature on pediatric ALCL, particularly in cases with complex cytogenetic profiles, and emphasizes the need for novel thera-peutic approaches and early intervention strategies.
Journal
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive
20d
P30CA033572: Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma (clinicaltrials.gov)
P2, N=48, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2024 --> Aug 2025
Trial completion date
|
ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
|
ALK positive • TNFRSF8 positive • ALK negative
|
doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Adcetris (brentuximab vedotin) • daunorubicin
21d
Crizotinib Treatment for Lorlatinib-resistant MET-amplified EML4-ALK-fusion Positive Advanced Lung Adenocarcinoma: A Case Report (PubMed, Zhongguo Fei Ai Za Zhi)
The patient developed resistance to Lorlatinib treatment accompanied by mesenchymal-epithelial transition factor (MET) amplification. Effective tumor control was achieved with the combined use of Crizotinib and Lorlatinib, providing a valuable reference for further exploration of treatment strategies following resistance to ALK-TKIs in clinical practice..
Journal
|
ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • EML4 (EMAP Like 4)
|
ALK positive • MET amplification • ALK fusion
|
Xalkori (crizotinib) • Lorbrena (lorlatinib)
21d
A comparative evaluation of alectinib for ALK-positive non-small-cell lung cancer: A systematic review. (PubMed, Medicine (Baltimore))
Alectinib has emerged as a viable, significantly superior treatment option for patients with ALK-positive NSCLC. The superior efficacy and manageable safety profile are significant; it remains a novel therapy with much potential, such as neoadjuvant therapy, which will make significant strides in patient care of ALK-positive NSCLC. Therefore, it is crucial for healthcare professionals, including surgeons, to be well-versed in alectinib and its potential. This knowledge will empower them and instill confidence in their ability to provide the best care for their patients.
Clinical • Review • Journal
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive
|
Alecensa (alectinib)
23d
Post Marketing Surveillance(PMS) Study of Lorviqua in Korea (clinicaltrials.gov)
P=N/A, N=600, Recruiting, Pfizer | Trial completion date: Aug 2028 --> Mar 2028 | Trial primary completion date: Aug 2028 --> Mar 2028
Trial completion date • Trial primary completion date
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive
|
Lorbrena (lorlatinib)
25d
Complete response to anti-PD1 therapy and chemotherapy in a patient with ALK-rearranged non-small cell lung cancer. (PubMed, Int J Clin Exp Pathol)
However, in previous studies, patients with ALK (Anaplastic Lymphoma Kinase) rearranged had a low response to immune checkpoint inhibitor (ICI) and the role of immunotherapy in ALK-positive NSCLC patients is unclear. Here, we report a case of a young man with ALK rearranged who demonstrated a complete response to anti-PD1 combination with chemotherapy, which suggests some ALK-rearranged patients with high expression of PD-L1 may permanently benefit from immunotherapy.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
|
PD-L1 overexpression • ALK positive • ALK rearrangement
25d
Hepatic adverse events associated with anaplastic lymphoma kinase tyrosine kinase inhibitors: a disproportionality analysis based on FAERS Database and analysis of drug-gene interaction network. (PubMed, Expert Opin Drug Saf)
Enriched KEGG pathways included the MAPK, PI3K-Akt, and Ras signaling. This pharmacovigilance study identifies significant AE signals linking ALK TKIs to liver injury, highlighting potential mechanisms and providing insights for clinical management and patient outcomes.
Journal • Adverse events
|
ALK (Anaplastic lymphoma kinase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
|
ALK positive
27d
The role of BIM gene deletion in ALK-mutated Non-small cell lung cancer treated with alectinib. (PubMed, Clin Exp Med)
Further experimental validation yielded that NSCLC with deleted BIM genes were less sensitive to aleitinib. BIM gene deletion can increase resistance to alectinib, and the potential efficacy of a combination of BIM sensitizer and alectinib to overcome alectinib resistance can be explored.
Journal
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive • ALK mutation
|
Alecensa (alectinib)
28d
The impact of PD-L1 expression status on the prognosis of ALK-positive lung cancer patients. (PubMed, Cancer Treat Res Commun)
PD-L1 positivity is common in ALK-positive lung cancer patients and correlates with poorer prognosis. PD-L1 serves as an independent predictor of adverse outcomes, indicating its potential as a biomarker for assessing lung cancer severity and prognosis.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
|
PD-L1 expression • ALK positive
29d
Comparative analysis of alectinib and brigatinib in real-world treatment of advanced NSCLC with ALK rearrangements. (PubMed, Ther Adv Med Oncol)
Alectinib and brigatinib demonstrated comparable efficacy in ALK-positive advanced NSCLC. Undergoing crizotinib followed by a second-generation TKI was not significantly different from initiating a second-generation TKI without prior crizotinib in terms of outcomes.
Journal • HEOR • Real-world evidence
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive • ALK rearrangement
|
Xalkori (crizotinib) • Alecensa (alectinib) • Alunbrig (brigatinib)
29d
A Rare Case of Isolated Central Nervous System Neoplasm With Histiocytic Features. (PubMed, Brain Tumor Res Treat)
The patient's condition improved following occupational rehabilitation therapy for right upper motor weakness, as well as anticonvulsant and radiation therapy, and her neurological condition remains stable. This case underscores the diagnostic challenges of Histiocytic Neoplasms and the necessity for interdisciplinary collaboration and sophisticated diagnostic techniques.
Journal
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive
1m
Expression and clinical significance of programmed death ligand-1 evaluated by 22C3 antibody in pleural effusion metastatic non-small-cell lung cancer. (PubMed, Cytojournal)
Immunohistochemical detection of PD-L1 expression in malignant pleural fluid of advanced NSCLC provides a basis for clinical tumor immunotherapy. Immunohistochemical detection of PD-L1 expression in malignant pleural fluid of advanced NSCLC is minimally invasive, simple, and fast, particularly for metastatic NSCLC where malignant pleural fluid is the first symptom, offering significant clinical application value.
Journal • Pleural effusion • PD(L)-1 Biomarker • IO biomarker
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
|
PD-L1 expression • EGFR mutation • ALK positive • EGFR expression
|
PD-L1 IHC 22C3 pharmDx
1m
Journal
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive
|
Lorbrena (lorlatinib)
1m
BRCA1-Associated Protein-1 Inactivated Melanoma Arising in a Pre-existing Nevus With ALK Fusion and Low Tumor Mutational Burden. (PubMed, Am J Dermatopathol)
The tumor was completely excised with negative margins. The patient is doing well at 17 months follow-up with no signs of recurrence.
Journal • Tumor mutational burden • BRCA Biomarker
|
BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • FGFR3 (Fibroblast growth factor receptor 3) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • TERT (Telomerase Reverse Transcriptase) • BAP1 (BRCA1 Associated Protein 1) • VHL (von Hippel-Lindau tumor suppressor) • RAF1 (Raf-1 Proto-Oncogene Serine/Threonine Kinase) • PRAME (Preferentially Expressed Antigen In Melanoma) • MAP2K7 (Mitogen-Activated Protein Kinase Kinase 7) • RREB1 (Ras Responsive Element Binding Protein 1)
|
TP53 mutation • BRAF V600E • BRAF V600 • ALK positive • TMB-L • ALK fusion • ALK mutation
1m
Brigatinib treatment in a patient with advanced NSCLC with XPO1-ALK fusion: a case report. (PubMed, Front Oncol)
In addition to reporting the identification of a novel ALK fusion, XPO1-ALK (intergenic), and the sensitivity and safety of brigatinib treatment for lung cancer, this study increased the list of known ALK fusion partners in ALK-positive NSCLC. This case report has a significant clinical reference.
Journal
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive • ALK rearrangement • ALK fusion
|
Alunbrig (brigatinib)
1m
Review • Journal • IO biomarker
|
ALK (Anaplastic lymphoma kinase) • EML4 (EMAP Like 4)
|
ALK positive • ALK rearrangement • ALK fusion
1m
Long-term survival of an ALK fusion lung adenocarcinoma patient with high mutation burden and microsatellite instability high: a case report. (PubMed, Anticancer Drugs)
The patient experienced progression on initial iruplinalkib and subsequent alectinib therapy within 5 months. After the failure of third-line therapy with cisplatin-pemetrexed combined with bevacizumab, she received sintilimab plus anlotinib which led to a progression-free survival of 6.5 months. She received sintilimab combined with albumin-paclitaxel plus carboplatin and achieved partial response after 6 months...After progression on ICB-based therapy, the patient was treated with lorlatinib and still under follow-up with overall survival of more than 3 years. Our findings highlight the therapeutic potential of ICB-based regimens in patients with MSI-H and ALK-rearranged NSCLC.
Journal • Tumor mutational burden • Microsatellite instability • MSi-H Biomarker • PD(L)-1 Biomarker
|
PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • EML4 (EMAP Like 4) • STK11 (Serine/threonine kinase 11) • MLH1 (MutL homolog 1)
|
PD-L1 expression • TP53 mutation • TMB-H • MSI-H/dMMR • ALK positive • ALK rearrangement • STK11 mutation • ALK fusion
|
Avastin (bevacizumab) • cisplatin • carboplatin • Focus V (anlotinib) • Tyvyt (sintilimab) • Alecensa (alectinib) • Lorbrena (lorlatinib) • albumin-bound paclitaxel • pemetrexed • Qi Xinke (iruplinalkib)
1m
Alectinib combined with VRCD and BV monoclonal antibody for the treatment of ALK-positive large B-cell lymphoma: a case report and literature review. (PubMed, Front Oncol)
The patient received three cycles of an "alectinib + Vincristine + Rituximab + Cyclophosphamide + Doxorubicin (VRCD) " regimen. In the fourth cycle, brentuximab vedotin monoclonal antibody treatment was added to increase the efficacy of the treatment...Thus far, the patient has undergone six treatment cycles and successfully received autologous hematopoietic stem cell transplantation. Currently, the patient is receiving maintenance therapy with alectinib and lenalidomide and remains in a favorable clinical condition.
Journal
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive
|
Rituxan (rituximab) • lenalidomide • Alecensa (alectinib) • bortezomib • doxorubicin hydrochloride • cyclophosphamide • Adcetris (brentuximab vedotin) • vincristine
1m
Diabetic Ketoacidosis During Lorlatinib Treatment: Case Report. (PubMed, J Thorac Oncol)
We present the case of a 65-year-old male patient with anaplastic lymphoma kinase-positive lung cancer and preexisting type 2 diabetes mellitus who developed diabetic ketoacidosis (DKA) after switching from alectinib to lorlatinib. After a 2-week interruption, lorlatinib was resumed at a reduced dose with satisfactory glycemic control. This case highlights the importance of vigilant glucose monitoring for patients receiving lorlatinib, especially those with preexisting diabetes, to prevent life-threatening complications such as DKA.
Journal
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive
|
Alecensa (alectinib) • Lorbrena (lorlatinib)
1m
M23-647: Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies (clinicaltrials.gov)
P1, N=244, Recruiting, AbbVie | N=128 --> 244 | Trial completion date: Apr 2029 --> Mar 2031 | Trial primary completion date: Jun 2027 --> Mar 2031
Enrollment change • Trial completion date • Trial primary completion date • Adverse events
|
ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
|
ALK positive
|
ABBV-101
1m
Spectrum and carcinogenic properties of thyroglobulin gene fusions in thyroid. (PubMed, Endocr Relat Cancer)
FDA-approved NTRK inhibitors entrectinib and larotrectinib effectively blocked TG::NTRK1 signaling in vitro and inhibited xenograft tumor growth in vivo. In summary, we report a spectrum of TG gene fusions as recurrent oncogenic events in thyroid cancer and NIFTP that drive strong overexpression of partner genes, frequently RTKs. The TG::NTRK1 fusion is prone to dimerization, activates oncogenic signaling, drives tumorigenesis in thyroid cells, and, like other fusions involving RTKs, represents a potential therapeutic target in thyroid cancer.
Journal
|
ALK (Anaplastic lymphoma kinase) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • FGFR1 (Fibroblast growth factor receptor 1) • IGF2 (Insulin-like growth factor 2) • IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1) • NTRK (Neurotrophic receptor tyrosine kinase) • TG (Thyroglobulin)
|
BRAF V600E • BRAF V600 • ALK positive
|
Vitrakvi (larotrectinib) • Rozlytrek (entrectinib)
1m
A Rare Head and Neck Tumor: Making Simple Things Complicated. (PubMed, Cureus)
This case underscores the importance of considering primary cutaneous ALCL in the differential diagnosis of persistent ulcerative lesions in anatomically sensitive areas. Early diagnosis, multidisciplinary management, and advanced therapeutic strategies such as Brentuximab Vedotin + Cyclophosphamide, Hydroxyrubicin, and Prednisone (BV + CHP) are critical to optimizing outcomes in this rare presentation.
Journal
|
ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
|
ALK positive • TNFRSF8 positive • ALK negative
|
Rituxan (rituximab) • cyclophosphamide • Adcetris (brentuximab vedotin) • prednisone